CHMP Recommends Pulling Novartis Sickle Cell Drug, Approves Two Other Drugs

By PacConAdmin | May 30, 2023

The European Medicines Agency’s (EMA) human medicines committee (CHMP) has recommended pulling a Novartis sickle cell disease drug from the market and approving two others to diagnose prostate cancer and treat a certain form of epilepsy.
Source: Drug Industry Daily

Posted in Drug Industry Daily